Work disability in non-radiographic axial spondyloarthritis patients before and after start of anti-TNF therapy: a population-based regional cohort study from southern Sweden

KARLSSON WALLMAN, JOHANLund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund Arthritis Research Group (LARG),Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups,Avdelningen för arbets- och miljömedicin,Institutionen för laboratoriemedicin,Miljöepidemiologi,Epidemiologi,Division of Occupational and Environmental Medicine, Lund University,Department of Laboratory Medicine,Environmental Epidemiology,Epidemiology (författare)

Objective. The aim was to assess work-loss days before and after commencement of anti-TNF treatment in patients with non-radiographic axial spondylarthritis (nr-axSpA). Methods. Bionaive nr-axSpA patients (n = 75), aged 17-62 years, fulfilling the Assessment of SpondyloArthritis international Society criteria for axial spondyloarthritis and starting anti-TNF treatment during 2004-11, were retrieved from the observational South Swedish Arthritis Treatment Group study. Patient information was linked to Swedish Social Insurance Agency data on sick leave and disability pension from 1 year before to 2 years after anti-TNF initiation. Matched population references were included for comparison and to adjust for secular trends. Results. The nr-axSpA patients had a median age of 35 years and disease duration of 6 years at the start of treatment. During the 2 years after anti-TNF initiation, mean work-loss days (including both sick leave and disability pension) in the nr-axSpA group decreased significantly from 3.4 to 1.9 times more than among the population references. The effect was seen on sick leave, whereas disability pension levels remained similar in both groups throughout. Conclusion. Anti-TNF therapy in nr-axSpA was associated with a significant and sustained improvement of work disability over 2 years. However, the proportion of work-loss days remained almost twice as high as in the general population at the end of follow-up.

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Reumatologi och inflammation hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Rheumatology and Autoimmunity hsv//eng
anti-TNF treatment
biologic treatment
spondyloarthritis
non-radiographic axial spondyloarthritis
work disability
sick leave
disability pension
ankylosing-spondylitis
sick leave
rheumatoid-arthritis
inception
cohort
necrosis-factor
2010 update
follow-up
etanercept
recommendations
criteria
Rheumatology
Anti-TNF treatment
Biologic treatment
Disability pension
Non-radiographic axial spondyloarthritis
Sick leave
Spondyloarthritis
Work disability

Joud, A. (författare)
Olofsson, TorLund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)med-t_o (författare)
Jacobsson, Lennart T. H.,1954Lund University,Lunds universitet,Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research,Internmedicin - epidemiologi,Forskargrupper vid Lunds universitet,Internal Medicine - Epidemiology,Lund University Research Groups(Swepub:lu)orto-lja (författare)
Bliddal, H.Copenhagen University Hospital (författare)
Kristensen, Lars E.Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Copenhagen University Hospital(Swepub:lu)med-lkr (författare)
Reumatologi och molekylär skelettbiologiSektion III (creator_code:org_t)

Ingår i:Rheumatology: Oxford University Press (OUP)56:5, s. 716-7241462-03241462-0332

Av författaren/redakt...: KARLSSON WALLMAN ...; Joud, A.; Olofsson, Tor; Jacobsson, Lenna ...; Bliddal, H.; Kristensen, Lars ...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Reumatologi och ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.